New drug combo tested to fight fatty liver in diabetics
NCT ID NCT07274644
Summary
This study aims to see if a combination diabetes drug (iGlarLixi) works better than standard insulin (iGlar) at reducing fat in the liver. It will involve 36 adults who have both type 2 diabetes and a fatty liver condition called MASLD. Participants will take one of the two treatments, along with metformin, for 12 weeks while researchers measure changes in liver fat using a special MRI scan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
Conditions
Explore the condition pages connected to this study.